CCI clears merger of nine pharma entities with Sequent Scientific

SSL offers active pharmaceutical ingredients (APIs), finished dosage formulations, and analytical services for the animal health sector

cci
Sequent Research Ltd (SRL), a wholly-owned subsidiary of SSL, is a contract research organisation. | Photo: PTI
Press Trust of India New Delhi
2 min read Last Updated : Jan 21 2025 | 10:28 PM IST

The Competition Commission on Tuesday cleared the proposed amalgamation of nine entities with pharmaceutical firm Sequent Scientific Ltd (SSL).

"The proposed combination involves a series of inter-connected steps carried out for the amalgamation of SRL, Viyash, Symed, Appcure, Vindhya Pharma, Vandana, Vindhya Organics, Geninn and SV Labs with SSL as the ultimate surviving entity," CCI (Competition Commission of India) said in a release.

SSL offers active pharmaceutical ingredients (APIs), finished dosage formulations, and analytical services for the animal health sector.

Sequent Research Ltd (SRL), a wholly-owned subsidiary of SSL, is a contract research organisation.

Viyash is a pharmaceutical company and through its subsidiaries is primarily engaged in the development, manufacture and sale of APIs and intermediates for human healthcare in India.

Symed Labs, Appcure Labs, Vindhya Pharma (India) and Vandana Life Sciences are wholly-owned subsidiaries of Viyash while S V Labs is a wholly owned step-down subsidiary of Viyash.

The amalgamation will streamline operations and strengthen SSL's position in both the animal and human healthcare segments.

In another release, CCI said it approved the proposed acquisition of AI Lenarco Midco by Majesty II Pte Ltd and certain compulsory convertible debentures in Manjushree Technopack from AI Lenarco by Ashoka India Equity Investment Trust plc, Nuvama Private Investment Trust and InCred Growth Partners Fund I.

Manjushree Technopack is engaged in the business of manufacturing and sale of rigid plastics packaging products in India.

"The proposed combination involves the acquisition by Majesty II Pte. Ltd of the entire equity shareholding in AI Lenarco Midco Ltd., which will result in indirect acquisition of the majority equity shareholding in Manjushree Technopack Ltd," CCI said.

The Majesty II Pte Ltd is an special purpose vehicle, and an investment holding company of the PAG group. PAG group is a leading alternative investment firm focused on the Asia-Pacific region.

Ashoka India Equity Investment Trust is a closed-ended investment company incorporated in England & Wales. Nuvama Private Investment Trust is a Sebi-registered Alternative Investment Fund (AIF).

InCred Growth Partners Fund I is a Sebi-registered AIF that invests in high quality private businesses across consumer, banking and financial services. AI Lenarco Midco is a Cyprus-based investment holding company of Advent International group.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Sequent Scientific Competition Commission of IndiaPharma Companies

First Published: Jan 21 2025 | 10:28 PM IST

Next Story